Investment deals (institutional investors only)

AKL Therapeutics
Therapeutics Stevenage, UK
  • Raising
    $15,000,000
  • Stage
    Series A
Matter Bioworks
Therapeutics New York, NY, US
  • Raising
    $10,000,000
  • Stage
    Seed
NaNotics
Therapeutics Mill Valley, CA, US
  • Raising
    $100,000,000
  • Stage
    Series B
Mitrix Bio
Therapeutics Pleasanton, CA, US
  • Raising
    $45,000,000
  • Stage
    Series A
YouthBio Therapeutics
Therapeutics Seattle, WA, US
  • Raising
    $7,500,000
  • Stage
    Seed
NURO
Neurotech Waterloo, Canada
  • Raising
    $20,000,000
  • Stage
    Series A
Ponce De Leon Health
Supplements Fernandian Beach, FL, US
  • Raising
    $10,000,000
  • Stage
    Series C
Daily Colors Health
Supplements Brentwood, CA, US
  • Raising
    $2,500,000
  • Stage
    Seed
Ridgeline Therapeutics
Therapeutics Houston, TX, US
  • Raising
    $10,000,000
  • Stage
    Series A
Oxford Drug Design

   

Therapeutics Oxford, UK
  • Raising
    $12,000,000
  • Stage
    Series A
BrainKey
Digital Health San Francisco, CA, US
  • Raising
    -
  • Stage
    -
Occuity
Medical Device Reading, UK
  • Raising
    £5,000,000
  • Stage
    Series A
Yuva Biosciences
Therapeutics Birmingham, AL, US
  • Raising
    $2,000,000
  • Stage
    Seed

Investment briefing

Full year 2022 report on the state of longevity investment: the numbers, the sectors, the top deals, the key players and the outlook for 2023:
Annual Longevity Investment Report
Read now
Disease management to disease modification – removing plaque to undo atherosclerosis:
Atherosclerosis
Read now
Delaying the menopause to increase women’s healthspan:
Reproductive longevity
Read now
Leading a new era of personalised, preventative health and optimal aging:
Longevity diagnostics
Read now
Supplementing your Longevity supplement knowledge:
Longevity supplements
Read now
Managing senescent cells to drive human longevity:
Senotherapeutics
Read now

News

New data suggest investigational osteoarthritis drug may have promising senotherapeutic effect

AKL Therapeutics’ investigational oral osteoarthritis drug APPA may have a dual effect…

TruDiagnostic and NADMED partner on new NAD blood diagnostic

Using novel test, US healthcare providers can test patients’ NAD+ levels at…

Longevity investment bulletin: Celmatix, BlueRock, TruDiagnostic and more

The latest longevity updates from our investment news desk.  Celmatix unveils largest…

Retro: A longevity biotech triple-threat?

Joe Betts-LaCroix on investing in longevity biotech and Retro’s progress in cellular…

Company alerts

  • March 20, 2023
    Histogen
    Histogen (NAS: HSTO)
    Also known as: #N/A
    LT 2203
    203 of 520
    Histogen is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair.
    Longevity pillar
    • Renewal
    • Treatment
    Longevity domain:
    • Regeneration
    • Advanced Aesthetics
    Location: United States
    Year founded: 01-Jan-07
    Longevity target: Aging Disease
    Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of March 21, 2023
    announces US patent covering CTS-2090 for inflammatory diseases. Read more
  • March 17, 2023
    The
    Oura
    Oura Health
    Also known as: Ōura
    LT 2339
    339 of 520
    Oura Health is the developer of a wellness wearable ring designed to track and improve the quality of sleep and performance. The company's product tracks sleep quality, stages, ECG level resting heart rate and variability as well as body temperature during the night through an intelligent data-driven plan by detecting changes in blood pulse volume, enabling users to improve their sleep, overall health, and align to their natural circadian rhythm.
    Longevity pillar
    • Prevention
    Longevity domain:
    • Longevity lifestyle
    Location: Finland
    Year founded: 01-Jan-13
    Longevity target: Longevity determinant
    Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of March 21, 2023
    ring just got new sleep features that even the Apple Watch doesn’t have. Read more
  • March 17, 2023
    TruDiagnostic
    TruDiagnostic
    Also known as: #N/A
    LT 2441
    441 of 520
    Founded in 2020, TruDiagnostic has already been making headway in the longevity industry with a mission to improve people's lives. TruDiagnostic wants to arm patients and physicians with information, enabling them to make the right decisions at the right times through insights found in the fluid epigenome
    Longevity pillar
    • Diagnostic
    • Prevention
    Longevity domain:
    • Longevity diagnostics
    Location: United States
    Year founded: 01-Jan-20
    Longevity target: Aging Driver
    Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of March 21, 2023
    and NADMED launch new blood diagnostic in US. Read more
  • March 16, 2023
    BlueRock Therapeutics
    BlueRock Therapeutics
    Also known as: BlueRock
    LT 2075
    75 of 520
    BlueRock is a developer of a new generation of authentic and engineered cell therapies created to impact various diseases. The company develops induced pluripotent stem cell therapies to cure a range of diseases with the help of regenerative medicines across neurology, cardiology and immunology indications, thus enabling healthcare professionals to deliver advanced care and ensure fast recovery of the patients suffering from intractable diseases. BlueRock has a superior understanding and know-how of the intricate requirements needed to differentiate pluripotent cells into specific cells in the body – neuronal cells, cardiac cells, immune cells and more.
    Longevity pillar
    • Renewal
    • Treatment
    Longevity domain:
    • Regeneration
    • Longevity Genetics
    Location: United States
    Year founded: 01-Jan-16
    Longevity target: Aging Disease, Aging Driver
    Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of March 21, 2023
    to use Rune Labs' clinical trial platform to better characterize Parkinson's disease state in cell therapy trials. Read more
  • March 16, 2023
    Celmatix
    Celmatix
    Also known as: #N/A
    LT 2097
    97 of 520
    Celmatix is a preclinical-stage biotech transforming women’s lives through better ovarian health.
    Longevity pillar
    • Treatment
    Longevity domain:
    • Discovery platforms
    • Reproductive longevity
    Location: United States
    Year founded: 01-Jan-09
    Longevity target: Aging Driver, Aging Disease
    Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of March 21, 2023
    and global collaborators release findings from largest genetic study to date on endometriosis. Read more
  • March 16, 2023
    Cambrian
    Cambrian Biopharma
    Also known as: #N/A
    LT 2084
    84 of 520
    Cambrian Biopharma is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. Over the next 10 or 15 years, Cambrian wants to bring the way that we treat the diseases of aging into the 21st century by preventing them from happening, instead of waiting for people to get sick
    Longevity pillar
    • Prevention
    Longevity domain:
    • Longevity platforms
    • Longevity drugs
    Location: United States
    Year founded: 01-Jan-19
    Longevity target: Aging Driver
    Proprietary analysis by Longevity.Technology, according to Pitchbook Data data as of March 21, 2023
    Bio reveals new pipeline company with focus on AMPK activation. Read more